GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humanigen Inc (OTCPK:HGENQ) » Definitions » Altman Z-Score

Humanigen (Humanigen) Altman Z-Score : -231.89 (As of Apr. 28, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Humanigen Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Humanigen has a Altman Z-Score of -231.89, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Humanigen's Altman Z-Score or its related term are showing as below:


Humanigen Altman Z-Score Historical Data

The historical data trend for Humanigen's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humanigen Altman Z-Score Chart

Humanigen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -308.70 - 12.73 -21.33 -109.71

Humanigen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.80 -28.51 -52.39 -109.71 -231.70

Competitive Comparison of Humanigen's Altman Z-Score

For the Biotechnology subindustry, Humanigen's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Humanigen's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humanigen's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Humanigen's Altman Z-Score falls into.



Humanigen Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Humanigen's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-9.4351+1.4*-134.0874+3.3*-10.0532+0.6*0.0004+1.0*0.3321
=-231.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2023:
Total Assets was $5.12 Mil.
Total Current Assets was $5.03 Mil.
Total Current Liabilities was $53.30 Mil.
Retained Earnings was $-685.99 Mil.
Pre-Tax Income was -4.182 + 4.39 + -23.693 + -30.149 = $-53.63 Mil.
Interest Expense was -0.018 + -0.118 + -1.298 + -0.768 = $-2.20 Mil.
Revenue was 0.221 + 0.221 + 0.221 + 1.036 = $1.70 Mil.
Market Cap (Today) was $0.02 Mil.
Total Liabilities was $54.84 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(5.026 - 53.296)/5.116
=-9.4351

X2=Retained Earnings/Total Assets
=-685.991/5.116
=-134.0874

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-53.634 - -2.202)/5.116
=-10.0532

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=0.024/54.841
=0.0004

X5=Revenue/Total Assets
=1.699/5.116
=0.3321

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Humanigen has a Altman Z-Score of -231.89 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Humanigen  (OTCPK:HGENQ) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Humanigen Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Humanigen's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Humanigen (Humanigen) Business Description

Traded in Other Exchanges
N/A
Address
830 Morris Turnpike, 4th Floor, Short Hills, NJ, USA, 07078
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.
Executives
Dale Chappell 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Adrian Kilcoyne officer: Chief Medical Officer 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
Cameron Durrant director 90, FAIRMOUNT ROAD WEST, CALIFON NJ 07830-3330
Edward P. Jordan officer: Chief Commercial Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Yili Kevin Xie director C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Black Horse Capital Lp 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Black Horse Capital Master Fund Ltd. 10 percent owner C/O OPUS EQUUM, INC., P.O. BOX 788, DOLORES CO 81323
Nomis Bay Ltd. 10 percent owner C/O EOM MANAGEMENT LTD., ANDREW'S PLACE, 51 CHURCH ST., 5TH FLOOR, HAMILTON D0 HM12
Cheryl Buxton director 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
Cheval Holdings, Ltd. 10 percent owner P.O. BOX 309G, UGLAND HOUSE, GEORGETOWN, GRAND CAYMAN E9 KY1-1104
Black Horse Capital Management Llc 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Robert G. Savage director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Rainer J. Boehm director C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
J Gregory Jester officer: Chief Financial Officer C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022

Humanigen (Humanigen) Headlines

From GuruFocus